POINT Biopharma Global Inc. (PNT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
POINT Biopharma Global Inc. (PNT) trades at $12.50 with AI Score 59/100 (Grade B). POINT Biopharma Global Inc. is a radiopharmaceutical company focused on developing and commercializing radioligands for cancer treatment. Market cap: $1.33B, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for PNT: PNT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PNT against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PNT: the 3 scored disciplines are evenly split.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
POINT Biopharma Global Inc. (PNT) Healthcare & Pipeline Overview
POINT Biopharma Global Inc. is a radiopharmaceutical company specializing in the development of radioligands for cancer treatment, with a focus on prostate and neuroendocrine tumors. Their pipeline includes Phase III trials and preclinical studies, positioning them within the growing radiopharmaceutical market.
What Is the Investment Thesis for PNT?
POINT Biopharma Global Inc. presents a compelling investment thesis based on its promising pipeline of radiopharmaceutical therapies, particularly PNT2002 and PNT2003, both in Phase III trials. The company's focus on precision medicine and targeted radioligand therapies addresses a significant unmet need in cancer treatment. The market capitalization of $1.33B reflects investor confidence in the company's potential. A key value driver is the successful completion and commercialization of PNT2002 and PNT2003. Upcoming data readouts from the Phase III trials will serve as major catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other pharmaceutical companies developing cancer therapies.
Based on FMP financials and quantitative analysis
PNT Key Highlights
- Market capitalization of $1.33B indicates investor confidence in POINT Biopharma's potential.
- P/E ratio of 12.03 suggests the company is potentially undervalued compared to its earnings.
- Gross margin of 100.0% reflects the high value of the company's radiopharmaceutical products.
- Profit margin of 43.4% demonstrates efficient operations and strong profitability.
- Lead product candidates, PNT2002 and PNT2003, are in Phase III clinical trials, indicating advanced stages of development.
Who Are PNT's Competitors?
PNT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CBIO Crescent Biopharma, Inc. | $15.05 | +2.03% | $415M | — |
| CINC CinCor Pharma, Inc. | $29.06 | +0.00% | $1.27B | 47 |
| CTIC CTI BioPharma Corp. | $9.10 | +0.06% | $1.20B | 56 |
| EQRX EQRx, Inc. | $2.34 | -2.09% | $1.14B | — |
| ETHZ ETHZ | $3.53 | +0.00% | $56.4M | 52 |
| XERS Xeris Biopharma Holdings, Inc. | $8.60 | -2.27% | $1.48B | 95 |
| INVA Innoviva, Inc. | $21.28 | -1.98% | $1.57B | 90 |
| CVAC CureVac N.V. | $4.66 | +0.00% | $1.05B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PNT's Key Strengths?
- Advanced clinical pipeline with Phase III assets.
- Proprietary radioligand technology platform.
- Experienced management team.
- Strong intellectual property portfolio.
What Are PNT's Weaknesses?
- Reliance on clinical trial success.
- High research and development costs.
- Limited commercial infrastructure.
- Dependence on sub-licensed technologies.
What Could Drive PNT Stock Higher?
- Data readouts from Phase III clinical trials for PNT2002 in metastatic castration-resistant prostate cancer.
- Data readouts from Phase III clinical trials for PNT2003 in neuroendocrine tumors.
- Enrollment and progress in Phase III clinical trials for PNT2002 and PNT2003.
- Development and advancement of PNT2001, the next-generation PSMA-targeting product candidate.
- Expansion of the pipeline through the CanSEEK technology platform.
What Are the Key Risks for PNT?
- Financial-distress signal — its Altman Z-Score of -25.77 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures for PNT2002 and PNT2003.
- Regulatory hurdles and delays in obtaining FDA approval.
- Competition from other pharmaceutical companies developing cancer therapies.
- High research and development costs.
- Dependence on sub-licensed technologies.
What Are the Growth Opportunities for PNT?
- Successful completion and commercialization of PNT2002 for metastatic castration-resistant prostate cancer (mCRPC) represents a significant growth opportunity. Timeline: Potential FDA approval and commercial launch within the next 2-3 years.
- Advancement and commercialization of PNT2003 for neuroendocrine tumors (NETs) offers another substantial growth avenue. The NETs market is also growing, and PNT2003's somatostatin-targeted approach could provide a differentiated treatment option. Timeline: Potential FDA approval and commercial launch within the next 2-3 years, contingent on Phase III trial outcomes.
- Development and commercialization of PNT2001, the next-generation PSMA-targeting product candidate for non-metastatic castration-sensitive prostate cancer, presents a long-term growth opportunity. This expands POINT Biopharma's reach within the prostate cancer market. Timeline: Preclinical studies ongoing, with potential clinical trials in the next 1-2 years.
- Expansion of the pipeline through the CanSEEK technology platform, sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited, allows for the development of new radiopharmaceutical therapies targeting various cancer types. This provides a diversified approach to growth. Timeline: Ongoing research and development, with potential new product candidates entering preclinical studies in the next year.
- Strategic partnerships and collaborations with other pharmaceutical companies and research institutions can accelerate the development and commercialization of POINT Biopharma's product candidates. This can provide access to new technologies, funding, and market expertise. Timeline: Ongoing efforts to establish strategic partnerships.
What Opportunities Does PNT Have?
- Expansion into new cancer indications.
- Strategic partnerships and collaborations.
- Out-licensing of technologies and product candidates.
- Growing radiopharmaceutical market.
What Threats Does PNT Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other pharmaceutical companies.
- Patent infringement.
What Are PNT's Competitive Advantages?
- Proprietary radioligand technology platform.
- Advanced clinical pipeline with Phase III assets.
- Strong intellectual property portfolio.
- Expertise in radiopharmaceutical development and manufacturing.
What Does PNT Do?
POINT Biopharma Global Inc., founded in 2019 and headquartered in Indianapolis, Indiana, is a radiopharmaceutical company dedicated to developing and commercializing radioligands to combat cancer. The company's mission is to transform cancer care through precision radiopharmaceutical therapies. Their lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand currently in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Another key asset is PNT2003, a somatostatin-targeted radioligand also in Phase III trials, targeting neuroendocrine tumors (NETs). In addition to these late-stage programs, POINT Biopharma is actively developing PNT2001, a next-generation PSMA-targeting product candidate for non-metastatic castration-sensitive prostate cancer, which is currently in preclinical studies. Furthermore, PNT-2004, a fibroblast activation protein-a (FAP-a) targeting program, is being developed for use in various tumor types and is also in preclinical development. The company leverages its CanSEEK technology, sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited, to develop additional product candidates. POINT Biopharma is committed to advancing radiopharmaceutical therapies to improve outcomes for cancer patients.
What Products and Services Does PNT Offer?
- Develop radioligand therapies for cancer treatment.
- Focus on precision medicine and targeted therapies.
- Conduct Phase III clinical trials for lead product candidates.
- Develop next-generation PSMA-targeting product candidates.
- Utilize CanSEEK technology for product development.
- Target prostate cancer and neuroendocrine tumors.
How Does PNT Make Money?
- Develop and commercialize radiopharmaceutical products.
- Generate revenue through sales of approved therapies.
- Out-license technologies and product candidates.
- Collaborate with other pharmaceutical companies.
What Industry Does PNT Operate In?
The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and significant potential for innovation. The radiopharmaceutical market is a growing segment within the broader biotechnology landscape, driven by advancements in targeted therapies and precision medicine. POINT Biopharma Global Inc. is positioned to capitalize on this trend with its focus on radioligand therapies for cancer. Competitors include companies like CBIO, CINC, CTIC, EQRX, and ETHZ, which are also developing cancer treatments.
Who Are PNT's Key Customers?
- Cancer patients
- Oncologists
- Hospitals
- Cancer treatment centers
Company Profile
POINT Biopharma Global Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Indianapolis, US. The company is led by CEO Joe A. McCann. PNT has traded publicly since 2020.
F-Score 6/9Financial Health
POINT Biopharma Global Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -25.77 places it in the distress zone, a signal of elevated financial risk.
ROE 26%Key Financial Metrics
Return on equity for POINT Biopharma Global Inc. stands at 26.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.0%, showing how much profit it generates from its asset base. PNT trades at a trailing price-to-earnings ratio of 12.03, below the Healthcare sector average of ~23x. Its free cash flow yield is 12.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.3%, the inverse of the P/E and a quick read on earnings relative to price.
PNT Valuation & Market Position
With a $1.33B market cap, POINT Biopharma Global Inc. sits in the small-cap segment of the market. Relative to its peer group, PNT's quantitative score of 59/100 is roughly in line with the peer average of 52/100.
PNT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see long-term value, potentially signaling confidence in the company's pipeline.
- The community is buzzing about potential partnerships, indicating optimism regarding POINT Biopharma's strategic direction and future growth.
- Positive sentiment around upcoming clinical trial results creates a favorable outlook, with many anticipating positive data releases.
- Market perception views the company as undervalued compared to its peers, pointing to potential upside as the market corrects its valuation.
Bear Case
- Some insiders have recently reduced their positions, which may indicate concerns about near-term performance or alternative investment opportunities.
- There's a segment of the community worried about increasing competition in the radiopharmaceutical space, potentially impacting POINT Biopharma's market share.
- Bearish sentiment is building around potential delays in the regulatory approval process, which could push back revenue generation.
- The market is showing some skepticism about the company's ability to successfully commercialize its products, raising concerns about long-term profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PNT Latest News
No recent news available for PNT.
PNT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PNT.
Price Targets
Wall Street price target analysis for PNT.
PNT MoonshotScore
What does this score mean?
The MoonshotScore rates PNT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Joe A. McCann
CEO
Joe A. McCann serves as the Chief Executive Officer of POINT Biopharma Global Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on oncology and radiopharmaceuticals. He has held leadership positions at various companies, contributing to the development and commercialization of innovative therapies. McCann's expertise spans across drug development, clinical trials, regulatory affairs, and commercial strategy. He is known for his strategic vision and ability to drive growth in the biotechnology sector.
Track Record: Under Joe A. McCann's leadership, POINT Biopharma Global Inc. has advanced its lead product candidates, PNT2002 and PNT2003, into Phase III clinical trials. He has overseen the expansion of the company's pipeline and the development of its CanSEEK technology platform. McCann has also been instrumental in securing strategic partnerships and collaborations to support the company's growth. His leadership has contributed to the company's market capitalization of $1.33B.
PNT Healthcare Stock FAQ
What does the AI Score mean for PNT?
PNT holds an AI Score of 59/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. POINT Biopharma Global Inc. is a radiopharmaceutical company focused on developing and commercializing radioligands for cancer treatment. The company's lead product candidates target prostate …
What does POINT Biopharma Global Inc. do?
POINT Biopharma Global Inc. is a radiopharmaceutical company focused on developing and commercializing radioligand therapies for cancer treatment. Their lead product candidates, PNT2002 and PNT2003, are in Phase III clinical trials targeting metastatic castration-resistant prostate cancer and neuroendocrine tumors, respectively. The company also has preclinical programs focused on next-generation PSMA-targeting agents and fibroblast activation protein-a (FAP-a) targeting.
What do analysts say about PNT stock?
Analyst coverage of POINT Biopharma Global Inc. is pending AI analysis. However, key valuation metrics to consider include the company's market capitalization of $1.33B and its P/E ratio of 12.03. Growth considerations revolve around the successful completion and commercialization of PNT2002 and PNT2003, as well as the advancement of its preclinical pipeline.
What are the main risks for PNT?
The main risks for POINT Biopharma Global Inc. include the potential for clinical trial failures, particularly for its lead product candidates PNT2002 and PNT2003. Regulatory hurdles and delays in obtaining FDA approval also pose a significant risk. Competition from other pharmaceutical companies developing cancer therapies could impact market share and pricing.
How does POINT Biopharma Global Inc. navigate regulatory approval processes?
POINT Biopharma Global Inc. navigates regulatory approval processes, primarily with the FDA, by adhering to strict clinical trial protocols and data collection standards. The company maintains ongoing communication with regulatory agencies to address any concerns and ensure compliance. Their regulatory strategy involves comprehensive documentation, rigorous data analysis, and proactive engagement with regulatory bodies throughout the drug development lifecycle.
What revenue streams does POINT Biopharma Global Inc. have in healthcare?
Currently, POINT Biopharma Global Inc. does not have established revenue streams as it is still in the clinical development stage. Potential future revenue streams will primarily depend on the successful commercialization of its lead product candidates, PNT2002 and PNT2003, upon regulatory approval. Revenue will be generated through direct sales of these radiopharmaceutical therapies to hospitals and cancer treatment centers.
What are the key factors to evaluate for PNT?
POINT Biopharma Global Inc. (PNT) holds an AI score of 59/100 (moderate). Not financial advice.
How frequently does PNT data refresh on this page?
PNT's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PNT's recent stock price performance?
POINT Biopharma Global Inc. (PNT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Advanced clinical pipeline with Phase III assets. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for PNT. Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain and can impact the company's prospects.